Clinical and Biostatistics Core

Information

  • Research Project
  • 10260847
  • ApplicationId
    10260847
  • Core Project Number
    U19AI162130
  • Full Project Number
    1U19AI162130-01
  • Serial Number
    162130
  • FOA Number
    RFA-AI-20-008
  • Sub Project Id
    9473
  • Project Start Date
    9/1/2021 - 2 years ago
  • Project End Date
    5/31/2026 - 2 years from now
  • Program Officer Name
  • Budget Start Date
    7/1/2021 - 2 years ago
  • Budget End Date
    6/30/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/19/2021 - 2 years ago

Clinical and Biostatistics Core

Project Summary/Abstract ? Clinical and Biostatistics Core The Clinical and Biostatistics Core (CBC) is a central component of the Evaluating Modes of Influenza Transmission (EMIT-2) program. The overall objective of this core is to perform a series of randomized clinical studies of influenza transmission to comprehensively evaluate viral, host, physical, and environmental factors that facilitate efficient human-to-human influenza transmission. In these studies, healthy participants who have no or very low levels of hemagglutination inhibiting antibodies to the current year?s vaccine strains will spend up to four days in contact with participants naturally infected with influenza virus and recruited by Research Project 1 (RP1). Each study in the series will employ an environmental intervention and a personal protection intervention designed by Research Project 2 (RP2). The core will provide the platform for collection of clinical and environmental samples by each of the two projects and the Advanced Bioaerosol Technology Core (ABTC). The clinical research facility for this project, Pharmaron Baltimore, has a long history of collaboration with the University of Maryland Center for Vaccine Development and is a site for the NIAID CIVIC program. The goals of this core will be achieved through the following specific aims: (1) Provide regulatory and safety infrastructure for a randomized controlled trial of influenza transmission; (2) Screen for healthy adult volunteers (Recipients), willing to temporarily reside on an inpatient containment unit approximately 2 weeks during the influenza season, and index cases with acute influenza infection (Donors); and (3) Expose un-infected eligible volunteers to influenza-infected index case patients. An independent Data and Safety Monitoring Board will be assembled to provide safety oversight over the conduct of the transmission studies. Ultimate oversight of the CBC?s activity will be the responsibility of the Core Leader (Dr. Chen) and Co-Investigator (Dr. Ortiz) and will include close coordination with the Projects and Cores of this U19.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U19
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    1008400
  • Indirect Cost Amount
    13625
  • Total Cost
  • Sub Project Total Cost
    1022025
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAID:1022025\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIV OF MARYLAND, COLLEGE PARK
  • Organization Department
  • Organization DUNS
    790934285
  • Organization City
    COLLEGE PARK
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    207425141
  • Organization District
    UNITED STATES